Latest News

3rd June, 2019

OncoImmunity starts a personalized cancer vaccine project with a Chinese biotech company

OncoImmunity teams up with an innovative China based high-tech biotechnology company that has developed a dendritic cell-based vaccine delivery platform. The Chinese vaccine company is developing a personalized cancer vaccine solution with its platform that promises to deliver potent anti-tumor immune responses in vaccinated patients. 

The collaboration will demonstrate the power of the Immuneoprofilerâ„¢ to predict accurate neoantigen targets for alleles that have high frequency in the human population, but little data in the publicly available databases. Such collaborations therefore demonstrate the ability of the Immuneoprofilerâ„¢ platform to guide personalized cancer immunotherapy for the Chinese and other Asian markets.

Please enable your browser to accept cookies and refresh this page to enjoy the best experience from this website and to dismiss this message.
In order to provide you with the best online experience this website uses cookies. By using our website, you agree to our use of cookies.OK